ABNX — Abionyx Pharma SA Balance Sheet
0.000.00%
Last trade - 00:00
- €35.17m
- €34.45m
- €4.64m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 8.33 | 9.15 | 7.93 | 4.05 | 4.1 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.73 | 0.617 | 3.93 | 2.75 | 2.3 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 10.1 | 10 | 13 | 7.57 | 6.89 |
Net Property, Plant And Equipment | 0.093 | 0.115 | 3.07 | 2.56 | 2.21 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 10.2 | 10.3 | 21.8 | 15.8 | 14.8 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.47 | 3.6 | 6.75 | 5.09 | 3.92 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 3.58 | 3.66 | 11.2 | 8.65 | 6.91 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 6.67 | 6.63 | 10.7 | 7.17 | 7.92 |
Total Liabilities & Shareholders' Equity | 10.2 | 10.3 | 21.8 | 15.8 | 14.8 |
Total Common Shares Outstanding |